268 related articles for article (PubMed ID: 21294847)
1. Binding site analysis of CCR2 through in silico methodologies: docking, CoMFA, and CoMSIA.
Kothandan G; Gadhe CG; Madhavan T; Cho SJ
Chem Biol Drug Des; 2011 Jul; 78(1):161-74. PubMed ID: 21294847
[TBL] [Abstract][Full Text] [Related]
2. Studies of tricyclic piperazine/piperidine furnished molecules as novel integrin αvβ3/αIIbβ3 dual antagonists using 3D-QSAR and molecular docking.
Yan Y; Li Y; Zhang S; Ai C
J Mol Graph Model; 2011 Feb; 29(5):747-62. PubMed ID: 21273104
[TBL] [Abstract][Full Text] [Related]
3. Docking and 3D-QSAR (quantitative structure activity relationship) studies of flavones, the potent inhibitors of p-glycoprotein targeting the nucleotide binding domain.
Kothandan G; Gadhe CG; Madhavan T; Choi CH; Cho SJ
Eur J Med Chem; 2011 Sep; 46(9):4078-88. PubMed ID: 21723648
[TBL] [Abstract][Full Text] [Related]
4. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore and docking-based combined in-silico study of KDR inhibitors.
Pasha FA; Muddassar M; Neaz MM; Cho SJ
J Mol Graph Model; 2009 Aug; 28(1):54-61. PubMed ID: 19447057
[TBL] [Abstract][Full Text] [Related]
6. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
7. Molecular docking and 3D QSAR studies on 1-amino-2-phenyl-4-(piperidin-1-yl)-butanes based on the structural modeling of human CCR5 receptor.
Xu Y; Liu H; Niu C; Luo C; Luo X; Shen J; Chen K; Jiang H
Bioorg Med Chem; 2004 Dec; 12(23):6193-208. PubMed ID: 15519163
[TBL] [Abstract][Full Text] [Related]
8. 3D-QSAR studies of JNK1 inhibitors utilizing various alignment methods.
Madhavan T; Chung JY; Kothandan G; Gadhe CG; Cho SJ
Chem Biol Drug Des; 2012 Jan; 79(1):53-67. PubMed ID: 21722320
[TBL] [Abstract][Full Text] [Related]
9. Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors.
Zeng H; Zhang H
J Mol Graph Model; 2010 Aug; 29(1):54-71. PubMed ID: 20471293
[TBL] [Abstract][Full Text] [Related]
10. QSAR studies on CCR2 antagonists with chiral sensitive hologram descriptors.
Nair PC; Srikanth K; Sobhia ME
Bioorg Med Chem Lett; 2008 Feb; 18(4):1323-30. PubMed ID: 18258426
[TBL] [Abstract][Full Text] [Related]
11. 3D-QSAR CoMFA/CoMSIA models based on theoretical active conformers of HOE/BAY-793 analogs derived from HIV-1 protease inhibitor complexes.
da Cunha EF; Sippl W; de Castro Ramalho T; Ceva Antunes OA; de Alencastro RB; Albuquerque MG
Eur J Med Chem; 2009 Nov; 44(11):4344-52. PubMed ID: 19616874
[TBL] [Abstract][Full Text] [Related]
12. Combined 3D-QSAR, molecular docking, and molecular dynamics study on piperazinyl-glutamate-pyridines/pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.
Hao M; Li Y; Wang Y; Yan Y; Zhang S; Li G; Yang L
J Chem Inf Model; 2011 Oct; 51(10):2560-72. PubMed ID: 21923153
[TBL] [Abstract][Full Text] [Related]
13. Homology modeling in tandem with 3D-QSAR analyses: a computational approach to depict the agonist binding site of the human CB2 receptor.
Cichero E; Ligresti A; Allarà M; di Marzo V; Lazzati Z; D'Ursi P; Marabotti A; Milanesi L; Spallarossa A; Ranise A; Fossa P
Eur J Med Chem; 2011 Sep; 46(9):4489-505. PubMed ID: 21835510
[TBL] [Abstract][Full Text] [Related]
14. Binding site exploration of CCR5 using in silico methodologies: a 3D-QSAR approach.
Gadhe CG; Kothandan G; Cho SJ
Arch Pharm Res; 2013 Jan; 36(1):6-31. PubMed ID: 23325486
[TBL] [Abstract][Full Text] [Related]
15. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
[TBL] [Abstract][Full Text] [Related]
16. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models.
Puntambekar DS; Giridhar R; Yadav MR
Eur J Med Chem; 2008 Jan; 43(1):142-54. PubMed ID: 17448576
[TBL] [Abstract][Full Text] [Related]
17. 3D-QSAR and molecular docking studies of 2-pyrimidinecarbonitrile derivatives as inhibitors against falcipain-3.
Potshangbam AM; Tanneeru K; Reddy BM; Guruprasad L
Bioorg Med Chem Lett; 2011 Dec; 21(23):7219-23. PubMed ID: 22018459
[TBL] [Abstract][Full Text] [Related]
18. 3D-QSAR studies on the inhibitors of AP-1 and NF-kappaB mediated transcriptional activation.
Qin J; Liu H; Li J; Ren Y; Yao X; Liu M
Eur J Med Chem; 2009 Jul; 44(7):2888-95. PubMed ID: 19128859
[TBL] [Abstract][Full Text] [Related]
19. QSAR study of a large set of 3-pyridyl ethers as ligands of the alpha4beta2 nicotinic acetylcholine receptor.
Zhang H; Li H; Ma Q
J Mol Graph Model; 2007 Jul; 26(1):226-35. PubMed ID: 17208024
[TBL] [Abstract][Full Text] [Related]
20. 3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies.
Thaimattam R; Daga P; Rajjak SA; Banerjee R; Iqbal J
Bioorg Med Chem; 2004 Dec; 12(24):6415-25. PubMed ID: 15556759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
